In a nutshell

ISOLDA will demonstrate the feasibility and broad applicability of improving vaccine effectiveness in older adults by introducing immunomodulators that counter immunosenescence.

We will do this by using …

  • Licensed vaccines for short/medium-term valorization (influenza and TBE)
  • New generation vaccines under clinical development (emerging coronaviruses, such as MVA-MERS or SARS-CoV-2)
  • Experimental vaccines under pre-clinical development (MERS and/or SARS-CoV-2 replicon)

Four objectives,
four viruses

Targeting four viruses, we have defined the following project objectives.

Improved vaccination strategies for older adults

Work packages

The project is divided into 4 work packages (WPs), each with its own set of milestones and deliverables. A brief description of each WP is provided over the sections below.

WP1

Characterization of immunosenescent signatures upon infection and vaccination in older adults

WP1 aims at assessing ageing effects on infection- and vaccine-induced immune responses. WP1 will evaluate human immune responses to infection with influenza virus, TBEV, MERS-CoV and/or SARS-CoV-2, and human immune responses to influenza, YF, TBE, MERS and/or SARS-CoV-2  vaccination. Specifically, the expression levels of immunosenescence markers, the strength and functionality of vaccine-specific T cell responses and the efficacy of antibody-mediated immunity will be compared in older vs. younger individuals, in relation to vaccine safety, efficacy and (break-through) infection. Data will be stratified for age and gender.

Identification of modulators of immunosenescence restoring immune responses ex vivo

WP2 aims at the selection of kinase inhibitors and inflammageing modulators that effectively overcome T cell senescence while limiting unproductive inflammation ex vivo. Data will be stratified according to age and gender.

WP2
WP3

Evaluation of selected modulators of immunosenescence for their ability to improve licensed vaccines and vaccine candidates in vivo

WP3 aims at assessing the capacity of lead combinations of immunomodulators, to improve the efficacy of licensed vaccines and vaccine candidates in animal models.

Tiered phase I clinical trial of one improved seasonal influenza vaccine candidate

WP4 aims at evaluation of the (improved) safety, tolerability and immunogenicity in human volunteers of the most promising seasonal influenza vaccine improved with the lead combination of immunomodulators, based on results obtained upon in WP3 in vivo studies.

WP4
WP5

Project management and dissemination

WP5 will support the overall scientific and financial management of the project, including scientific and financial reporting, assessment of progress towards the project’s objectives, evaluation of deviations and implementation of mitigation measures. It will also be responsible for the development and implementation of dissemination, protection and exploitation of ISOLDA’s results, and will oversee ISOLDA’s communication activities.

WP1

Characterization of immunosenescent signatures upon infection and vaccination in older adults

WP1 aims at assessing ageing effects on infection- and vaccine-induced immune responses. WP1 will evaluate human immune responses to infection with influenza virus, TBEV and SARS-CoV-2, and human immune responses to influenza, YF, TBE and SARS-CoV-2  vaccination. Specifically, the expression levels of immunosenescence markers, the strength and functionality of vaccine-specific T cell responses and the efficacy of antibody-mediated immunity will be compared in older vs. younger individuals, in relation to vaccine safety, efficacy and (break-through) infection. Data will be stratified for age and gender.

WP2

Identification of modulators of immunosenescence restoring immune responses ex vivo

WP2 aims at the selection of kinase inhibitors and inflammageing modulators that effectively overcome T cell senescence while limiting unproductive inflammation ex vivo. Data will be stratified according to age and gender.

WP3

Evaluation of selected modulators of immunosenescence for their ability to improve licensed vaccines and vaccine candidates in vivo

WP3 aims at assessing the capacity of lead combinations of immunomodulators, to improve the efficacy of licensed vaccines and vaccine candidates in animal models.

WP4

Tiered phase I clinical trial of one improved seasonal influenza vaccine candidate

WP4 aims at evaluation of the (improved) safety, tolerability and immunogenicity in human volunteers of the most promising seasonal influenza vaccine improved with the lead combination of immunomodulators, based on results obtained upon in WP3 in vivo studies.

WP5

Project management and dissemination

WP5 will support the overall scientific and financial management of the project, including scientific and financial reporting, assessment of progress towards the project’s objectives, evaluation of deviations and implementation of mitigation measures. It will also be responsible for the development and implementation of dissemination, protection and exploitation of ISOLDA’s results, and will oversee ISOLDA’s communication activities.

The ISOLDA project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 848166.